Novartis plans to close an oral solid-dosage manufacturing facility in Broomfield, Colorado that is owned by its generics arm, Sandoz. Approximately 450 jobs will be affected as a result of the closure.

The move results from Sandoz’s plan to stop production of some generic drugs due to double-digit price erosion in the US market. The closure and transfer will extend over an approximate two-year period. The last phase is expected to close in the fourth quarter of 2019. Novartis will consolidate the production of drug products to a plant in Wilson, North Carolina.

Novartis continues to have a strong presence in the US, employing more than 23,000 people at 24 sites across the country.

Source: Novartis